Etiological treatment in patients infected by Trypanosoma cruzi: experiences in Argentina.
OBJECTIVE
The aim of this review is to describe knowledge, mainly of the last 15 years, that changed criteria for specific treatment against Trypanosoma cruzi infection.


RESULTS
Over the past 15 years, there has been an increase in the use of new methodologies to evaluate the efficacy of antiparasitic treatments. These tools showed that the evaluation period for trypanocidal treatment effectiveness could be shortened. Based on the hypothesis that Chagas' cardiomyopathy may indeed be triggered by persistent parasitic infection, it seems plausible that trypanocidal therapy may delay, reduce or prevent the progression to the disease.


CONCLUSIONS
Based on the present knowledge, we can assume that every patient infected with Trypanosoma cruzi in the acute phase and in the early chronic phase (i.e. children under 16 years old) must be treated, and adults could be treated. In this area, research priorities should target obtaining new drugs to allow shorter treatments with fewer adverse reactions and improving new tools to confirm cure when patients are treated during the Chronic Phase.
Sosa-Estani
Sergio
S
Centro Nacional de Diagnóstico e Investigación de Endemo-epidemias (CeNDIE), Ministerio de Salud y Ambiente, Buenos Aires, Argentina. ssosa@msal.gov.ar
Segura
Elsa Leonor
EL
D001118:Argentina; D014355:Chagas Disease / Q000188:drug therapy* / Q000469:parasitology / Q000503:physiopathology; D006801:Humans; D016896:Treatment Outcome; D014344:Trypanocidal Agents / Q000627:therapeutic use*
D014344:Trypanocidal Agents